Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
IssuerBlackrock
ETF TickerBTEE(USD) LSE
ETF TickerBTEE.L(GBP) LSE

Holdings detail for ARGX

Stock Nameargenx NV ADR
TickerARGX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS04016X1019
LEI7245009C5FZE6G9ODQ71

Show aggregate ARGX holdings

News associated with ARGX

Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts
(RTTNews) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives. Amylyx Pharmaceuticals, Amneal Pharmaceuticals, and argenx SE each marked notable gains on Septe - 2025-09-11 06:41:22
Bank of America Raises argenex (NASDAQ:ARGX) Price Target to $887.00
argenex (NASDAQ:ARGX – Get Free Report) had its target price increased by equities researchers at Bank of America from $880.00 to $887.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 22.85% from the stock’s […] - 2025-09-04 04:34:49
Wedbush Estimates argenex’s Q3 Earnings (NASDAQ:ARGX)
argenex SE (NASDAQ:ARGX – Free Report) – Analysts at Wedbush reduced their Q3 2025 earnings per share (EPS) estimates for argenex in a research report issued to clients and investors on Monday, August 25th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $5.60 per share for the quarter, down from […] - 2025-08-28 02:22:48
argenex (NASDAQ:ARGX) versus MaxCyte (NASDAQ:MXCT) Head to Head Analysis
MaxCyte (NASDAQ:MXCT – Get Free Report) and argenex (NASDAQ:ARGX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends. Risk and Volatility MaxCyte has a beta of 1.23, meaning […] - 2025-08-27 04:50:47
argenex (NASDAQ:ARGX) Price Target Raised to $820.00
argenex (NASDAQ:ARGX – Free Report) had its target price raised by Piper Sandler from $750.00 to $820.00 in a research report report published on Tuesday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock. Several other analysts also recently weighed in on ARGX. Oppenheimer lifted their price objective on shares of argenex from […] - 2025-08-27 03:06:44
argenex (NASDAQ:ARGX) Earns “Outperform” Rating from Wedbush
argenex (NASDAQ:ARGX – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They currently have a $800.00 target price on the stock. Wedbush’s price objective points to a potential upside of 12.98% from the stock’s previous close. ARGX has been […] - 2025-08-27 02:08:54
argenex (NASDAQ:ARGX) Now Covered by Analysts at Royal Bank Of Canada
Royal Bank Of Canada initiated coverage on shares of argenex (NASDAQ:ARGX – Free Report) in a research report report published on Monday, Marketbeat Ratings reports. The firm issued an outperform rating and a $850.00 price target on the stock. ARGX has been the subject of several other reports. Guggenheim increased their price objective on shares […] - 2025-08-26 03:10:54
Argenx's VYVGART Achieves Primary Endpoint In Pivotal Study For AChR-Ab Seronegative GMG
(RTTNews) - argenx SE (ARGX) reported that the pivotal ADAPT SERON study of VYVGART (IV: efgartigimod alfa-fcab) successfully met its primary endpoint. The study demonstrated a statistically significant and clinically meaningful improvement in MG-ADL (Myasthenia Gravis Activities - 2025-08-25 02:25:55
LPL Financial LLC Has $12.36 Million Position in argenex SE (NASDAQ:ARGX)
LPL Financial LLC lifted its holdings in shares of argenex SE (NASDAQ:ARGX – Free Report) by 28.0% during the first quarter, HoldingsChannel reports. The firm owned 20,880 shares of the company’s stock after acquiring an additional 4,563 shares during the quarter. LPL Financial LLC’s holdings in argenex were worth $12,358,000 as of its most recent […] - 2025-08-08 04:28:56
US Bancorp DE Sells 45 Shares of argenex SE (NASDAQ:ARGX)
US Bancorp DE decreased its stake in argenex SE (NASDAQ:ARGX – Free Report) by 0.9% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 4,835 shares of the company’s stock after selling 45 shares during the period. US Bancorp DE’s holdings in argenex were worth $2,862,000 as of its most recent filing with the […] - 2025-08-07 05:20:51
argenex SE (NASDAQ:ARGX) Stake Lowered by Avantax Advisory Services Inc.
Avantax Advisory Services Inc. reduced its stake in shares of argenex SE (NASDAQ:ARGX – Free Report) by 5.7% during the 1st quarter, HoldingsChannel reports. The fund owned 1,000 shares of the company’s stock after selling 61 shares during the period. Avantax Advisory Services Inc.’s holdings in argenex were worth $592,000 as of its most recent […] - 2025-08-05 05:52:53
Bank of New York Mellon Corp Buys 7,921 Shares of argenex SE (NASDAQ:ARGX)
Bank of New York Mellon Corp raised its holdings in shares of argenex SE (NASDAQ:ARGX – Free Report) by 124.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,283 shares of the company’s stock after buying an additional 7,921 shares […] - 2025-07-23 04:28:43
Ballentine Partners LLC Trims Stock Position in argenex SE (NASDAQ:ARGX)
Ballentine Partners LLC lessened its holdings in argenex SE (NASDAQ:ARGX – Free Report) by 7.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 495 shares of the company’s stock after selling 41 shares during the period. Ballentine Partners LLC’s holdings in argenex […] - 2025-07-17 05:33:09
argenex (NASDAQ:ARGX) Upgraded by Deutsche Bank Aktiengesellschaft to Buy Rating
Deutsche Bank Aktiengesellschaft upgraded shares of argenex (NASDAQ:ARGX – Free Report) from a hold rating to a buy rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. Several other analysts have also recently weighed in on ARGX. HC Wainwright reissued a “buy” rating and issued a $720.00 price target on shares […] - 2025-07-11 02:36:48
2,640 Shares in argenex SE (NASDAQ:ARGX) Acquired by Calamos Advisors LLC
Calamos Advisors LLC purchased a new position in shares of argenex SE (NASDAQ:ARGX – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,640 shares of the company’s stock, valued at approximately $1,563,000. Other hedge funds and other institutional investors have […] - 2025-07-07 06:01:03
argenex (NASDAQ:ARGX) Now Covered by Analysts at Morgan Stanley
Morgan Stanley assumed coverage on shares of argenex (NASDAQ:ARGX – Free Report) in a report published on Thursday morning. The brokerage issued an overweight rating and a $700.00 target price on the stock. A number of other equities analysts have also weighed in on ARGX. Citigroup reiterated a “buy” rating on shares of argenex in […] - 2025-07-04 04:59:45
Implied QQQJ Analyst Target Price: $36
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-03 08:21:16
Janney Montgomery Scott LLC Boosts Stake in argenex SE (NASDAQ:ARGX)
Janney Montgomery Scott LLC increased its position in shares of argenex SE (NASDAQ:ARGX – Free Report) by 41.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,141 shares of the company’s stock after buying an additional 335 shares during the quarter. Janney Montgomery Scott LLC’s holdings in argenex were worth $675,000 as of […] - 2025-07-02 05:37:06
Sequoia Financial Advisors LLC Boosts Stock Holdings in argenex SE (NASDAQ:ARGX)
Sequoia Financial Advisors LLC raised its stake in argenex SE (NASDAQ:ARGX – Free Report) by 1.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,829 shares of the company’s stock after acquiring an additional 24 shares during the period. Sequoia Financial Advisors LLC’s […] - 2025-07-01 05:50:51
Oppenheimer & Co. Inc. Has $542,000 Stock Position in argenex SE (NASDAQ:ARGX)
Oppenheimer & Co. Inc. lifted its stake in shares of argenex SE (NASDAQ:ARGX – Free Report) by 10.2% during the first quarter, Holdings Channel.com reports. The firm owned 915 shares of the company’s stock after acquiring an additional 85 shares during the period. Oppenheimer & Co. Inc.’s holdings in argenex were worth $542,000 as of […] - 2025-07-01 05:02:55
argenx SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Buy” from Brokerages
argenx SE (NASDAQ:ARGX – Get Free Report) has been assigned a consensus rating of “Buy” from the twenty-two brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. […] - 2025-06-16 02:52:48
HC Wainwright Reaffirms “Buy” Rating for argenx (NASDAQ:ARGX)
argenx (NASDAQ:ARGX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $720.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 25.23% from the stock’s previous close. A number […] - 2025-06-12 02:18:53
William Blair Estimates argenx’s Q2 Earnings (NASDAQ:ARGX)
argenx SE (NASDAQ:ARGX – Free Report) – Analysts at William Blair upped their Q2 2025 earnings estimates for shares of argenx in a note issued to investors on Thursday, May 29th. William Blair analyst M. Minter now expects that the company will earn $2.36 per share for the quarter, up from their previous estimate of […] - 2025-06-03 02:17:11
Analysts Anticipate 10% Upside For FTQI
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-02 07:09:27
argenx SE (NASDAQ:ARGX) Receives Average Recommendation of “Buy” from Brokerages
argenx SE (NASDAQ:ARGX – Get Free Report) has been given an average rating of “Buy” by the twenty-three analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, twenty have given a buy recommendation and two have issued a strong buy recommendation on the […] - 2025-05-22 02:46:43
argenx (NASDAQ:ARGX) Upgraded to Outperform at Robert W. Baird
Robert W. Baird upgraded shares of argenx (NASDAQ:ARGX – Free Report) from a neutral rating to an outperform rating in a report issued on Tuesday, MarketBeat Ratings reports. Robert W. Baird currently has $680.00 price target on the stock. Other analysts have also recently issued research reports about the company. Oppenheimer raised their price objective […] - 2025-05-14 05:36:47
argenx SE (NASDAQ:ARGX) Receives $699.28 Average PT from Analysts
argenx SE (NASDAQ:ARGX – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-three research firms that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to […] - 2025-04-30 02:47:05
Argenx Secures CHMP Recommendation For European Approval Of VYVGART SC Injection For CIDP Treatment
(RTTNews) - argenx SE (ARGX) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission approval of VYVGART 1000mg (efgartigimod alfa). This subcutaneous (SC) injection is proposed as a monot - 2025-04-28 02:15:50
Analysts Expect FTQI Will Reach $22
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-25 07:58:52
Cerity Partners LLC Sells 71 Shares of argenx SE (NASDAQ:ARGX)
Cerity Partners LLC cut its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 2.2% during the 4th quarter, Holdings Channel reports. The fund owned 3,202 shares of the company’s stock after selling 71 shares during the period. Cerity Partners LLC’s holdings in argenx were worth $1,801,000 as of its most recent SEC […] - 2025-04-17 04:36:51

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) ARGX holdings

DateNumber of ARGX Shares HeldBase Market Value of ARGX SharesLocal Market Value of ARGX SharesChange in ARGX Shares HeldChange in ARGX Base ValueCurrent Price per ARGX Share HeldPrevious Price per ARGX Share Held
2026-02-09 (Monday)21,258USD 17,606,726USD 17,606,726
2026-02-06 (Friday)21,211ARGX holding increased by 47USD 17,211,666ARGX holding decreased by -474666USD 17,211,66647USD -474,666 USD 811.45 USD 835.68
2026-02-02 (Monday)21,164USD 17,686,332ARGX holding decreased by -102010USD 17,686,3320USD -102,010 USD 835.68 USD 840.5
2026-01-30 (Friday)21,164ARGX holding increased by 94USD 17,788,342ARGX holding decreased by -73118USD 17,788,34294USD -73,118 USD 840.5 USD 847.72
2026-01-29 (Thursday)21,070ARGX holding increased by 47USD 17,861,460ARGX holding decreased by -311242USD 17,861,46047USD -311,242 USD 847.72 USD 864.42
2026-01-27 (Tuesday)21,023ARGX holding increased by 47USD 18,172,702ARGX holding increased by 696338USD 18,172,70247USD 696,338 USD 864.42 USD 833.16
2026-01-26 (Monday)20,976USD 17,476,364ARGX holding increased by 386378USD 17,476,3640USD 386,378 USD 833.16 USD 814.74
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ARGX by Blackrock for IE00BDZVHG35

Show aggregate share trades of ARGX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2026-02-06BUY47 811.450* -
2026-01-30BUY94855.060832.280 834.558USD 78,448 -
2026-01-29BUY47852.450840.550 841.740USD 39,562 -
2026-01-27BUY47881.890845.880 849.481USD 39,926 -
2026-01-23BUY94833.800810.515 812.844USD 76,407 -
2026-01-22BUY47827.580816.290 817.419USD 38,419 -
2026-01-16BUY875818.780795.020 797.396USD 697,722 -
2026-01-15BUY90813.980798.145 799.729USD 71,976 -
2026-01-14BUY90812.090797.880 799.301USD 71,937 -
2026-01-12BUY90799.870770.670 773.590USD 69,623 -
2026-01-09BUY135816.450787.440 790.341USD 106,696 -
2026-01-07BUY90830.295796.030 799.457USD 71,951 -
2026-01-02BUY45855.430839.320 840.931USD 37,842 -
2025-12-30BUY45841.180835.030 835.645USD 37,604 -
2025-12-23SELL-540856.590843.030 844.386USD -455,968 -
2025-12-19SELL-2,716863.105849.530 850.888USD -2,311,011 -
2025-12-17SELL-255878.060859.236 861.118USD -219,585 -
2025-12-16SELL-51858.435842.230 843.850USD -43,036 -
2025-12-15BUY102853.964827.520 830.164USD 84,677 -
2025-12-11BUY337897.040884.340 885.610USD 298,451 -
2025-12-04BUY1,020928.120915.850 917.077USD 935,419 -
2025-12-02BUY765919.820902.370 904.115USD 691,648 -
2025-11-28BUY51916.510905.225 906.353USD 46,224 -
2025-11-26BUY153928.990915.360 916.723USD 140,259 -
2025-11-26BUY153928.990915.360 916.723USD 140,259 -
2025-11-25BUY255920.160900.160 902.160USD 230,051 -
2025-11-24BUY51918.310897.500 899.581USD 45,879 -
2025-11-20SELL-204932.180912.920 914.846USD -186,629 -
2025-11-19BUY51928.120912.570 914.125USD 46,620 -
2025-11-18BUY306929.800908.160 910.324USD 278,559 -
2025-11-17BUY102933.900910.020 912.408USD 93,066 -
2025-11-14BUY51914.870880.970 884.360USD 45,102 -
2025-11-12BUY51907.470885.810 887.976USD 45,287 -
2025-11-10BUY51872.910852.390 854.442USD 43,577 -
2025-11-06BUY51855.700831.460 833.884USD 42,528 -
2025-11-04BUY51850.660824.700 827.296USD 42,192 -
2025-10-30BUY255830.495749.750 757.824USD 193,245 -
2025-10-29BUY146821.970842.185 840.163USD 122,664 -
2025-10-22SELL-204814.170839.660 837.111USD -170,771 -
2025-10-20BUY102849.460855.460 854.860USD 87,196 -
2025-10-17BUY255843.660849.990 849.357USD 216,586 -
2025-10-15BUY408815.610819.710 819.300USD 334,274 -
2025-10-03BUY350800.000803.740 803.366USD 281,178 -
2025-10-02BUY50791.590793.470 793.282USD 39,664 -
2025-09-30BUY100737.560741.050 740.701USD 74,070 -
2025-09-26BUY100711.620720.820 719.900USD 71,990 -
2025-09-25BUY100711.090723.250 722.034USD 72,203 -
2025-09-18BUY54731.770737.870 737.260USD 39,812 -
2025-09-17BUY165734.350755.665 753.533USD 124,333 -
2025-07-17SELL-108572.710573.480 573.403USD -61,928 -
2025-07-16BUY183577.920578.315 578.276USD 105,824 -
2025-07-11SELL-432560.240564.025 563.647USD -243,495 -
2025-07-02BUY2,970545.110554.395 553.467USD 1,643,796 -
2025-06-25BUY108560.530564.280 563.905USD 60,902 -
2025-06-20BUY191542.150546.910 546.434USD 104,369 -
2025-06-13BUY47577.890583.160 582.633USD 27,384 -
2025-06-11BUY106574.960582.011 581.306USD 61,618 -
2025-06-10BUY106575.460589.900 588.456USD 62,376 -
2025-06-04SELL-53573.505585.215 584.044USD -30,954 -
2025-04-23BUY53594.650603.150 602.300USD 31,922 -
2025-04-10SELL-424546.220564.790 562.933USD -238,684 -
2025-04-08SELL-53548.930577.415 574.566USD -30,452 -
2025-04-07SELL-53550.000560.348 559.313USD -29,644 -
2025-04-04SELL-265555.110582.723 579.962USD -153,690 -
2025-04-01BUY454567.090593.990 591.300USD 268,450 -
2025-03-31SELL-156591.865594.420 594.164USD -92,690 -
2025-03-21BUY535615.020619.920 619.430USD 331,395 -
2025-03-14SELL-800604.960605.430 605.383USD -484,306 -
2025-03-07SELL-100594.210612.400 610.581USD -61,058 -
2025-03-04SELL-50621.250633.640 632.401USD -31,620 -
2025-02-25BUY100624.940636.390 635.245USD 63,525 -
2025-02-19SELL-50640.140645.025 644.537USD -32,227 -
2025-02-13BUY150651.340652.230 652.141USD 97,821 -
2025-02-12BUY50649.090649.960 649.873USD 32,494 -
2025-02-11BUY200636.020647.205 646.087USD 129,217 -
2025-01-02BUY39620.160627.800 627.036USD 24,454 -
2024-12-30SELL-1,733619.960625.930 625.333USD -1,083,702 -
2024-11-18SELL-825567.900569.420 569.268USD -469,646 -
2024-11-08SELL-55596.000599.400 599.060USD -32,948 -
2024-10-21SELL-55560.450565.160 564.689USD -31,058 -
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARGX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1972,7632,502307,24323.7%
2025-09-1866,114100178,13637.1%
2025-09-1751,2960135,16038.0%
2025-09-1645,93325100,55845.7%
2025-09-1542,9561110,02239.0%
2025-09-1238,767569,60955.7%
2025-09-1171,58718148,57648.2%
2025-09-1055,2170107,93051.2%
2025-09-0999,9020145,24768.8%
2025-09-08100,5210142,65670.5%
2025-09-05103,2900193,13953.5%
2025-09-0498,380202204,61348.1%
2025-09-0386,1490197,39143.6%
2025-09-0241,152170125,43332.8%
2025-08-2973,3091,415119,29261.5%
2025-08-2842,5811121,58835.0%
2025-08-2767,1630120,30955.8%
2025-08-26125,0950179,94769.5%
2025-08-25125,620120232,99153.9%
2025-08-2249,311080,11961.5%
2025-08-2171,510130141,79950.4%
2025-08-2050,9033098,83051.5%
2025-08-1976,9851,806163,66447.0%
2025-08-1879,159519108,69472.8%
2025-08-1558,4871143,51040.8%
2025-08-1447,4221080,90758.6%
2025-08-1354,7120153,62635.6%
2025-08-1252,4860137,47838.2%
2025-08-1170,3670313,40522.5%
2025-08-0847,0962,281124,06238.0%
2025-08-0751,4351141,96136.2%
2025-08-0666,8872,216147,77745.3%
2025-08-0562,1061155,23940.0%
2025-08-0490,33245168,64153.6%
2025-08-01130,416135306,43842.6%
2025-07-31204,678150579,99035.3%
2025-07-30132,061285207,87863.5%
2025-07-2949,59118893,31553.1%
2025-07-2891,517869124,33873.6%
2025-07-25108,659742208,29652.2%
2025-07-2451,76747191,33627.1%
2025-07-2341,977083,17850.5%
2025-07-2241,16713575,07454.8%
2025-07-2141,1123265,37962.9%
2025-07-1851,29215383,42161.5%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.


Copyright Market Footprint Ltd. Privacy Policy